Key result
K2P3.1 channel inhibition reverses chronic atrial fibrillation-induced action potential shortening.
Why the study?
Does K(2P)3.1 channel inhibition reverse action potential duration shortening in patients with chronic atrial fibrillation?
Does K(2P)3.1 channel inhibition reverse action potential duration shortening in patients with chronic atrial fibrillation?
K(2P)3.1 channel inhibition reverses action potential duration shortening in chronic AF, highlighting its potential as a novel mechanism-based therapeutic target.
Answers are grounded in this paper and cite their sources.
K(2P)3.1 inhibition merits human study in chronic AF; animal data leave clinical translation open.
Enhancement of atrium-selective K(2P)3.1 currents contributes to APD shortening in patients with chronic AF, and K(2P)3.1 channel inhibition reverses AF-related APD shortening. These results highlight the potential of K(2P)3.1 as a novel drug target for mechanism-based AF therapy.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2015) studied this question. Upregulation of K2P3.1 K+ currents contributes to action potential shortening in chronic atrial fibrillation, which is reversed by K2P3.1 channel inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: